Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach

Virology

Volumn 331, Issue 1, 2005, Pages 82-93

  Tan, Gene S ^a   McKenna, Philip M ^a   Koser, Martin L ^a   McLinden, Robert ^b,c   Kim, Jerome H ^b,c   McGettigan, James P ^a   Schnell, Matthias J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b TRIPLER ARMY MEDICAL CENTER   (United States)

^c US Military HIV Research Program   (United States)

Author keywords

Boost; Immune response; Prime

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; BLOOD ANALYSIS; CELL SECRETION; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; RABIES VIRUS; VACCINIA VIRUS; VAGINA; VESICULAR STOMATITIS VIRUS; VIRUS EXPRESSION; VIRUS RECOMBINANT; VIRUS STRAIN;

AIDS VACCINES; ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE PRODUCTS, ENV; GENETIC VECTORS; HIV ANTIBODIES; HIV-1; IMMUNITY, CELLULAR; IMMUNITY, MUCOSAL; IMMUNIZATION SCHEDULE; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; RABIES VIRUS; RHABDOVIRIDAE; VACCINES, SYNTHETIC; VESICULAR STOMATITIS-INDIANA VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS; MACACA; MACACA MULATTA; RABIES VIRUS; RHABDOVIRIDAE; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS; VESICULAR STOMATITIS VIRUS;

EID: 9944222721     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2004.10.018     Document Type: Article

References (70)

1. R.R. Amara, F. Villinger, S.I. Staprans, J.D. Altman, D.C. Montefiori, N.L. Kozyr, Y. Xu, L.S. Wyatt, P.L. Earl, J.G. Herndon, H.M. McClure, B. Moss, and H.L. Robinson Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines J. Virol. 76 2002 7625 7631
2. D.H. Barouch, S. Santra, J.E. Schmitz, M.J. Kuroda, T.M. Fu, W. Wagner, M. Bilska, A. Craiu, X.X. Zheng, G.R. Krivulka, K. Beaudry, M.A. Lifton, C.E. Nickerson, W.L. Trigona, K. Punt, D.C. Freed, L. Guan, S. Dubey, D. Casimiro, A. Simon, M.E. Davies, M. Chastian, T.B. Strom, R.S. Gelman, D.C. Montefiori, M.G. Lewis, E.A. Emini, J.W. Shiver, and N.L. Shiver Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination Science 290 2000 486 492
3. D.H. Barouch, J. Kuntsman, M.J. Kuroda, J.E. Schmitz, S. Santra, F.W. Peyerl, G.R. Krivulka, K. Beaudry, M.A. Lifton, D.A. Gorgone, D.C. Montefiori, M.G. Lewis, S.M. Wolinsky, and N.L. Letvin Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes Nature 415 2002 335 339
4. D.H. Barouch, J. Kunstman, J. Glowczwskie, K.J. Kunstman, M.A. Egan, F.W. Peyerl, S. Santra, M.J. Kuroda, J.E. Schmitz, K. Beaudry, G.R. Krivulka, M.A. Lifton, D.A. Gorgone, S.M. Wolinsky, and N.L. Letvin Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys J. Virol. 77 2003 7367 7375
5. J.N. Blankson, D. Persaud, and R.F. Siliciano The challenge of viral reservoirs in HIV-1 infection Annu. Rev. Med. 53 2002 557 593
6. P. Borrow, H. Lewicki, B.H. Hahn, G.M. Shaw, and M.B. Oldstone Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection J. Virol. 68 1994 6103 6110
7. S.L. Buge, L. Murty, K. Arora, V.S. Kalyanaraman, P.D. Markham, E.S. Richardson, K. Aldrich, L.J. Patterson, C.J. Miller, S.-M. Cheng, and M. Robert-Guroff Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251 J. Virol. 73 1999 7430 7440
8. SF2 recombinant gp120, or both vaccines in seronegative adults J. Infect. Dis. 177 1998 1230 1236
9. M.P. Cranage, A.M. Whatmore, S.A. Sharpe, N. Cook, N. Polyanskaya, S. Leech, J.D. Smith, E.W. Rud, M.J. Dennis, and G.A. Hall Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa Virology 229 1997 143 154
10. J.M. Crawford, P.L. Earl, B. Moss, K.A. Reimann, M.S. Wyand, K.H. Manson, M. Bilska, J.T. Zhou, C.D. Pauza, P.W. Parren, D.R. Burton, J.G. Sodroski, N.L. Letvin, and D.C. Montefiori Characterization of primary isolate-like variants of simian-human immunodeficiency virus J. Virol. 73 1999 10199 10207
11. N. Dumais, A. Patrick, R.B. Moss, H.I. Davis, and K.L. Rosenthal Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge J. Infect. Dis. 186 2002 1098 1105
12. E.A. Emini, W.A. Schleif, J.H. Nunberg, A.J. Conley, Y. Eda, S. Tokiyoshi, S.D. Putney, S. Matsushrta, K.E. Cobb, C.M. Jett, J.W. Eichberg, and K.K. Murphy Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody Nature 355 1992 728 730
13. M.J. Estcourt, A.J. Ramsay, A. Brooks, S.A. Thomson, C.J. Medveckzy, and I.A. Ramshaw Prime-boost immunization generates a high frequency, high-avidity CD8+ cytotoxic T lymphocyte population Int. Immunol. 14 2002 31 37
14. B. Etemad-Moghadam, G.B. Karlsson, M. Halloran, Y. Sun, D. Schenten, M. Fernandes, N.L. Letvin, and J. Sodroski Characterization of simain-human immunodeficiency virus envelope glycoprotein epitopes recognized by neutralizing antibodies from infected monkeys J. Virol. 72 1998 8437 8445
15. F. Ferrantelli, and R.M. Ruprecht Neutralizing monoclonal antibodies against HIV-back in the major leagues? Curr. Opin. Immunol. 14 2002 495 502
16. F. Ferrantelli, R.A. Rasmussen, R. Hofmann-Lehmann, W. Xu, H.M. McClure, and R.M. Ruprecht Do not underestimate the power of antibodies-lessons from adoptive transfer of antibodies against HIV Vaccine 20 2002 A61 A65
17. A. Gallimore, M. Cranage, N. Cook, N. Almond, J. Bootman, E. Rund, P. Silvera, M. Dennis, T. Corcoran, and J. Stott Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques Nat. Med. 1 1995 1167 1173
18. M.M. Gherardi, J.L. Najera, E. Perez-Jimenez, S. Guerra, A. Garcia-Sastre, and M. Esteban Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes J. Virol. 77 2003 7048 7057
19. M.M. Gherardi, E. Perez-Jimenez, J.L. Najera, and M. Estaban Induction of HIV Immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule J. Immunol. 172 2004 6209 6220
20. R.M. Gonzalo, D. Rodriguez, A. Garcia-Sastre, J.R. Rodriguez, P. Palese, and M. Esteban Enhanced CD8 T cell response to HIV-1 Env by combined immunization with influenza and vaccinia virus recombinants Vaccine 17 1999 887 892
21. T.C. Greenough, D.B. Brettler, M. Somasundaran, D.O.L. Panicali, and J.L. Sullivan Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte (CTL), virus load, and CD4 T cell loss: evidence supporting a protective role for CTL in vivo J. Infect. Dis. 176 1997 118 125
22. K. Haglund, J. Forman, H.G. Krausslich, and J.K. Rose Expression of human immunodeficiency virus type 1 Gag protein precursor and envelope proteins from a vesicular stomatitis virus recombinant: high-level production of virus-like particles containing HIV envelope Virology 268 2000 112 121
23. K. Haglund, I. Leiner, K. Kerksiek, L. Buonocore, E. Pamer, and J.K. Rose Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 gag and Env proteins J. Virol. 76 2002 7506 7517
24. T. Hanke, A.J. McMichael, M. Mwau, E.G.-T. Wee, I. Ceberej, S. Patel, J. Sutton, M. Tomlinson, and R.V. Samuel Development of a DNA-MVA/HIVA vaccine for Kenya Vaccine 20 2002 1995 1998
25. R. Hofmann-Lehmann, J. Vlasak, R.A. Rasmussen, B.A. Smith, T.W. Baba, V. Liska, F. Ferrantelli, D.C. Montefiori, H.M. McClure, D.C. Anderson, B.J. Bernacky, T.A. Rizvi, R. Schmidt, L.R. Hill, M.E. Kneeling, H. Katinger, G. Steigler, L.A. Cavacini, M.R. Posner, T.C. Chou, J. Anderson, and R.M. Ruprecht Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge J. Virol. 75 2001 7470 7480
26. A.A. Horner, S.K. Datta, K. Takabayashi, I.M. Belyakov, T. Hayashi, N. Cinman, M.-D. Nguyen, J.H. Van Uden, J.A. Berzofsky, D.D. Richman, and E. Raz Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites J. Immunol. 167 2001 1584 1591
27. B.X. Jin, D.E. Bauer, S.E. Tuttleton, S. Lewin, A. Gettie, J. Blanchard, C.E. Irwin, J.T. Safrit, J. Mittler, L. Weinberger, L.G. Kostrikis, L. Zhang, A.S. Perelson, and D.D. Ho Dramatic rise in plasma viremia after CD8+T cell depletion in simian immunodeficiency virus-specific macaques J. Exp. Med. 189 1999 991 998
28. J.E. Johnson, M.J. Schnell, L. Buonocore, and J.K. Rose Specific targeting to CD4+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins J. Virol. 71 1997 5060 5068
29. J.E. Johnson, W. Rodgers, and J.K. Rose A plasma membrane localization signal in the HIV-1 envelope cytoplasmic domain prevents localization at sites of vesicular stomatitis virus budding and incorporation into VSV virions Virology 251 1998 244 252
30. S.M. Kaech, E.J. Wherry, and R. Ahmed Effector and memory T-cell differentiation: implications for vaccine development Nat. Rev., Immunol. 2 2002 251 262
31. S.J. Kent, A. Zhao, S.J. Best, J.D. Chandler, D.B. Boyle, and I.A. Ramshaw Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus J. Virol. 72 1998 10180 10188
32. J.H. Kim, P. Pitisuttithum, C. Kamboonruang, T. Chuenchitra, J. Mascola, S.S. Frankel, M.S. DeSouza, V. Polonis, R. McLinden, A. Sambor, A.E. Brown, B. Phonrat, K. Rungruengthanakit, A.M. Duliege, M.L. Robb, J. McNeil, and D.L. Birx Specific antibody responses to vaccination with bivalent CM235/SF2 gp120: detection of homologous and heterologous neutralizing antibody to subtype E (CRF01.AE) HIV type 1 AIDS Res. Hum. Retroviruses 19 9 2003 807 816
33. R.A. Koup, J.T. Safrit, Y. Cao, C.A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D.D. Ho Temporal association of cellular immune response with the initial control of viremia in primary HIV-1 syndrome J. Virol. 68 1994 4650 4655
34. P.D. Kwong, M.L. Doyle, D.J. Casper, C. Cicala, S.A. Leavitt, S. Majeed, T.D. Steenbeke, M. Venturi, I. Chaiken, M. Fung, H. Katinger, P.W. Parren, J. Robinson, D. Van Ryk, L. Wang, D.R. Burton, E. Freire, R. Wyatt, J. Sodroski, W.A. Hendrickson, and J. Arthos HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites Nature 420 2002 678 682
35. F. Lemiale, W.-P. Kong, L.M. Akyurek, X. Ling, Y. Huang, B.K. Chakrabarti, M. Eckhaus, and G.J. Nabel Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system J. Virol. 77 2003 10078 10087
36. C.K. Leonard, M.W. Spellman, L. Riddle, R.J. Harris, J.N. Thomas, and T.J. Gregory Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells J. Biol. Chem. 265 1990 10373 10382
37. N.L. Letvin, D.C. Montofiori, Y. Yasutomi, H.C. Perry, M.-E. Davies, C. Lekutis, M. Alroy, D.C. Freed, C.L. Lord, L.K. Handt, M.A. Liu, and J.W. Shiver Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination Proc. Natl. Acad. Sci. 94 1997 9378 9383
38. S. Li, M. Rodrigues, D. Rodrigues, J.R. Rodrigues, M. Esteban, P. Palese, R.S. Nussenzweig, and F. Zavala Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria Proc. Natl. Acad. Sci. 90 1993 5214 5218
39. N.J. Mantis, P.A. Kozlowski, D.W. Mielcarz, W. Weissenhorn, and M.R. Neutra Immunization of mice with recombinant gp41 in a systemic prime/mucosal boost protocol induces HIV-1-specific serum IgG and secretory IgA antibodies Vaccine 19 2001 3990 4001
40. J.R. Mascola, M.G. Lewis, G. Stiegler, D. Harris, T.C. VanCott, D. Hayes, M.K. Louder, C.R. Brown, C.V. Sapan, S.S. Frankel, Y. Lu, M.L. Robb, H. Katinger, and D.L. Birx Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies J. Virol. 73 1999 4009 4018
41. J.R. Mascola, G. Steigler, T.C. VanCott, H. Katinger, C.B. Carpenter, C.E. Hanson, H. Beary, D. Hayes, S.S. Frankel, D.L. Birx, and M.G. Lewis Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies Nat. Med. 6 2000 207 210
42. S.J. McConkey, W.H.H. Reece, V.S. Moorthy, D. Webster, S. Dunachie, G. Butcher, J.M. Vuola, T.J. Blanchard, P. Gothard, K. Watkins, C.M. Hannan, S. Everaere, K. Brown, K.E. Kester, J. Cummings, K. Williams, D.G. Heppner, A. Pathan, K. Flanagan, N. Arulanantham, M.T.M. Roberts, M. Roy, G.L. Smith, J. Schneider, T. Peto, R.E. Sinden, S.C. Gilbert, and A.V.S. Hill Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans Nat. Med. 9 2003 729 735
43. J.P. McGettigan, H.D. Foley, I.M. Belyakov, J.A. Berzofsky, R.J. Pomerantz, and M.J. Schnell Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates J. Virol. 75 2001 4430 4434
44. J.P. McGettigan, R.J. Pomerantz, C.A. Siler, P.M. McKenna, H.D. Foley, B. Dietzschold, and M.J. Schnell Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic J. Virol. 77 2003 237 244
45. J.A. McKeating, A. McKnight, and J.P. Moore Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization J. Virol. 65 1991 852 860
46. P.M. McKenna, R.J. Pomerantz, B. Dietzschold, J.P. McGettigan, and M.J. Schnell Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes J. Virol. 77 2003 12782 12794
47. A.J. McMichael T cell responses and viral escape Cell 93 1998 673 676
48. A.J. McMichael, and T. Hanke HIV vaccines 1983-2003 Nat. Med. 9 2003 874 880
49. A. McMichael, M. Mwau, and T. Hanke Design and tests of an HIV vaccine Br. Med. Bull. 62 2002 87 98
50. D.C. Montefiori, K.A. Reimann, M.S. Wyand, K. Manson, M.G. Lewis, R.G. Collman, J.G. Sodroski, D.P. Bolognesi, and N.L. Letvin Neutralizing antibodies in sera from macaques infected with chimeric simian-human immunodeficiency virus containing the envelope glycoproteins of either a laboratory-adapted variant or a primary isolate of human immunodeficiency virus type 1 J. Virol. 72 1998 3427
51. J.P. Moore, J.A. McKeating, R.A. Weiss, and Q.J. Sattentau Dissociation of gp120 from HIV-1 virions induced by soluble CD4 Science 250 1990 1139 1142
52. Y. Nakaya, H. Zheng, and A. Garcia-Sastre Enhanced cellular immune responses to SIV Gag by immunization with influenza and vaccinia virus recombinants Vaccine 21 2003 2097 2106
53. P.W. Parren, H.J. Ditzel, R.J. Gulizia, J.M. Binley, C.F. Barbas, D.R. Burton, and D.E. Mosier Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site AIDS 9 1995 F1 F6
54. P.W. Parren, J.P. Moore, D.R. Burton, and Q.J. Sattentau The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity AIDS 13 1999 S137 S162
55. P.W. Parren, P.A. Marx, A.J. Hessell, A. Luckay, J. Harouse, C. Cheng-Mayer, J.P. Moore, and D.R. Burton Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro J. Virol. 75 2001 8340 8347
56. T.M. Richardson Jr., B.L. Stryjewski, C.C. Broder, J.A. Hoxie, J.R. Mascola, P.L. Earl, and R.W. Doms Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein J. Virol. 70 1996 753 762
57. C. Rinaldo, X.L. Huang, Z.F. Fan, M. Ding, L. Beltz, A. Logar, D. Panicali, G. Mazzara, J. Liebmann, M. Cottrill, and P. Gupta High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors J. Virol. 69 1995 5838 5842
58. A. Roberts, E. Kretzschmar, A.S. Perkins, J. Forman, R. Price, L. Buonocore, Y. Kawaoka, and J.K. Rose Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge J. Virol. 72 1998 4704 4711
59. H.L. Robinson New hope for an AIDS vaccine Nat. Rev. 2 2002 239 250
60. N.F. Rose, A. Roberts, L. Buonocore, and J.K. Rose Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1 J. Virol. 74 2000 10903 10910
61. N.F. Rose, P.A. Marx, A. Luckay, D.F. Nixon, W.J. Moretto, S.M. Donahoe, D. Montefiori, A. Roberts, L. Buonocore, and J.K. Rose An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants Cell 106 2001 539 549
62. S. Rowland-Jones, J. Sutton, K. Ariyoshi, T. Dong, F. Gotch, S. McAdam, D. Whitby, S. Sabally, A. Gallimore, and T. Corrah HIV-specific cytotoxic T-cells in HIV exposed but uninfected Gambian women Nat. Med. 1 1995 59 64
63. J.T. Safrit, M.S. Fung, C.A. Andrews, D.G. Braun, W.N. Sun, T.W. Chang, and R.A. Koup Hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120 AIDS 7 1993 15 21
64. M.J. Schnell, T. Mebatsion, and K.K. Conzelmann Infectious rabies viruses from cloned cDNA EMBO J. 13 1994 4195 4203
65. M.J. Schnell, H.D. Foley, C.A. Siler, J.P. McGettigan, B. Dietzschold, and R.J. Pomerantz Recombinant rabies virus as potential live-viral vaccines for HIV-1 Proc. Natl. Acad. Sci. 97 2000 3544 3549
66. R.A. Seder, and A.V. Hill Vaccines against intracellular infections requiring cellular immunity Nature 406 2000 793 798
67. H.F. Staats, W.G. Nichols, and T.J. Palker Mucosal immunity to HIV-1 J. Immunol. 157 1996 462 472
68. R.A. Subbramanian, M.J. Kuroda, W.A. Charini, S.H. Barouch, C. Costantino, S. Santra, J.E. Schmitz, K.L. Martin, M.A. Lifton, A. Gorgone, J.W. Shiver, and N.L. Letvin Magnitude and diversity of cytotoxic-T-lymphocyte responses elicited by multiepitope DNA vaccination in rhesus monkeys J. Virol. 77 2003 10113 10118
69. T. Woodberry, J. Gardner, S.L. Elliot, S. Leyrer, D.M. Purdie, P. Chaplin, and A. Suhrbier Prime boost vaccination strategies: CD8 T cell numbers, protection, and Th1 bias J. Immunol. 170 2003 2599 2604
70. O.O. Yang Will we be able to 'spot' an effective HIV-1 vaccine Trends Immunol. 24 2003 67 72